Abstract
Background. Chemoradiation improves survival for patients with locally advanced non-small cell lung cancer (NSCLC), but clinical outcomes beyond five years are rarely reported. The aim of the present study was to identify the long-term results of a phase II study of docetaxel and cisplatin with concurrent thoracic radiation. Methods. We previously reported short-term outcomes from the phase II study, which enrolled 42 patients (aged ≤ 75 years) with unresectable stage III NSCLC. We continued to follow these patients for long-term clinical outcomes. Results. At a median follow-up for all patients of 6.3 years (range: 5.27.1 years), the median survival time was 2.1 years and the actual five-year survival rate was 31%. Among 14 patients who were progression-free longer than two years, three patients died due to bacterial or fungal pneumonia and one died due to gall bladder cancer. Conclusions. Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. Progression-free patients might be cautiously followed up taking precautions against emerging pneumonia.
| Original language | English |
|---|---|
| Pages (from-to) | 537-540 |
| Number of pages | 4 |
| Journal | Acta Oncologica |
| Volume | 51 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2012 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Hematology
Cite this
Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. / Tokuda, Yoshiyuki; Takigawa, Nagio; Kozuki, Toshiyuki; Kamei, Haruhito; Bessho, Akihiro; Tada, Atsuhiko; Hotta, Katsuyuki; Katsui, Kuniaki; Kanazawa, Susumu; Tanimoto, Mitsune; Kiura, Katsuyuki.
In: Acta Oncologica, Vol. 51, No. 4, 04.2012, p. 537-540.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer
AU - Tokuda, Yoshiyuki
AU - Takigawa, Nagio
AU - Kozuki, Toshiyuki
AU - Kamei, Haruhito
AU - Bessho, Akihiro
AU - Tada, Atsuhiko
AU - Hotta, Katsuyuki
AU - Katsui, Kuniaki
AU - Kanazawa, Susumu
AU - Tanimoto, Mitsune
AU - Kiura, Katsuyuki
PY - 2012/4
Y1 - 2012/4
N2 - Background. Chemoradiation improves survival for patients with locally advanced non-small cell lung cancer (NSCLC), but clinical outcomes beyond five years are rarely reported. The aim of the present study was to identify the long-term results of a phase II study of docetaxel and cisplatin with concurrent thoracic radiation. Methods. We previously reported short-term outcomes from the phase II study, which enrolled 42 patients (aged ≤ 75 years) with unresectable stage III NSCLC. We continued to follow these patients for long-term clinical outcomes. Results. At a median follow-up for all patients of 6.3 years (range: 5.27.1 years), the median survival time was 2.1 years and the actual five-year survival rate was 31%. Among 14 patients who were progression-free longer than two years, three patients died due to bacterial or fungal pneumonia and one died due to gall bladder cancer. Conclusions. Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. Progression-free patients might be cautiously followed up taking precautions against emerging pneumonia.
AB - Background. Chemoradiation improves survival for patients with locally advanced non-small cell lung cancer (NSCLC), but clinical outcomes beyond five years are rarely reported. The aim of the present study was to identify the long-term results of a phase II study of docetaxel and cisplatin with concurrent thoracic radiation. Methods. We previously reported short-term outcomes from the phase II study, which enrolled 42 patients (aged ≤ 75 years) with unresectable stage III NSCLC. We continued to follow these patients for long-term clinical outcomes. Results. At a median follow-up for all patients of 6.3 years (range: 5.27.1 years), the median survival time was 2.1 years and the actual five-year survival rate was 31%. Among 14 patients who were progression-free longer than two years, three patients died due to bacterial or fungal pneumonia and one died due to gall bladder cancer. Conclusions. Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. Progression-free patients might be cautiously followed up taking precautions against emerging pneumonia.
UR - http://www.scopus.com/inward/record.url?scp=84859773469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859773469&partnerID=8YFLogxK
U2 - 10.3109/0284186X.2011.631580
DO - 10.3109/0284186X.2011.631580
M3 - Article
VL - 51
SP - 537
EP - 540
JO - Acta Oncologica
JF - Acta Oncologica
SN - 0284-186X
IS - 4
ER -